 Gregory Kinney
Concepts (389)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pulmonary Disease, Chronic Obstructive | 52 | 2024 | 1114 | 5.580 |
Why?
| | Coronary Artery Disease | 27 | 2023 | 639 | 1.950 |
Why?
| | Tomography, X-Ray Computed | 40 | 2023 | 2403 | 1.770 |
Why?
| | Diabetes Mellitus, Type 1 | 37 | 2022 | 3361 | 1.700 |
Why?
| | Smokers | 16 | 2023 | 148 | 1.590 |
Why?
| | Smoking | 25 | 2023 | 1457 | 1.490 |
Why?
| | Cannabis | 8 | 2023 | 381 | 1.430 |
Why?
| | Forced Expiratory Volume | 24 | 2024 | 517 | 1.210 |
Why?
| | Pulmonary Emphysema | 11 | 2023 | 318 | 1.180 |
Why?
| | Bronchiectasis | 7 | 2023 | 107 | 1.100 |
Why?
| | Calcinosis | 17 | 2015 | 256 | 1.030 |
Why?
| | Respiratory Function Tests | 11 | 2021 | 523 | 0.930 |
Why?
| | Diabetic Ketoacidosis | 3 | 2022 | 169 | 0.900 |
Why?
| | Hyperlipidemias | 2 | 2023 | 125 | 0.900 |
Why?
| | Lung | 20 | 2023 | 3588 | 0.860 |
Why?
| | Marijuana Smoking | 3 | 2022 | 219 | 0.850 |
Why?
| | Cardiovascular System | 1 | 2023 | 125 | 0.840 |
Why?
| | Dronabinol | 3 | 2021 | 118 | 0.830 |
Why?
| | Diabetic Angiopathies | 11 | 2016 | 259 | 0.730 |
Why?
| | Volatilization | 1 | 2019 | 62 | 0.700 |
Why?
| | Middle Aged | 79 | 2023 | 27170 | 0.690 |
Why?
| | Diabetes Mellitus, Type 2 | 5 | 2023 | 2159 | 0.690 |
Why?
| | Nebulizers and Vaporizers | 1 | 2019 | 78 | 0.680 |
Why?
| | Cannabinoids | 4 | 2023 | 116 | 0.670 |
Why?
| | Spirometry | 14 | 2024 | 258 | 0.610 |
Why?
| | Coronary Vessels | 7 | 2021 | 227 | 0.590 |
Why?
| | Risk Factors | 35 | 2023 | 8873 | 0.590 |
Why?
| | Air Pollution | 1 | 2019 | 184 | 0.590 |
Why?
| | Cardiovascular Diseases | 5 | 2023 | 1782 | 0.590 |
Why?
| | Marijuana Abuse | 1 | 2019 | 207 | 0.580 |
Why?
| | Female | 96 | 2023 | 60630 | 0.570 |
Why?
| | Humans | 120 | 2024 | 117047 | 0.570 |
Why?
| | Male | 88 | 2023 | 56660 | 0.540 |
Why?
| | Vascular Calcification | 5 | 2019 | 117 | 0.520 |
Why?
| | 1-Alkyl-2-acetylglycerophosphocholine Esterase | 2 | 2016 | 20 | 0.520 |
Why?
| | Disease Progression | 24 | 2021 | 2467 | 0.520 |
Why?
| | Risk Assessment | 8 | 2019 | 3021 | 0.500 |
Why?
| | Aged | 38 | 2022 | 19356 | 0.480 |
Why?
| | Cohort Studies | 28 | 2023 | 5050 | 0.470 |
Why?
| | Adult | 50 | 2023 | 31003 | 0.430 |
Why?
| | Prospective Studies | 24 | 2023 | 6389 | 0.410 |
Why?
| | Atherosclerosis | 4 | 2023 | 343 | 0.390 |
Why?
| | Coronary Disease | 7 | 2010 | 352 | 0.390 |
Why?
| | Airway Obstruction | 2 | 2024 | 165 | 0.370 |
Why?
| | Pulmonary Artery | 4 | 2022 | 1025 | 0.370 |
Why?
| | Emphysema | 2 | 2023 | 123 | 0.360 |
Why?
| | Depression | 4 | 2022 | 1137 | 0.340 |
Why?
| | Prevalence | 12 | 2023 | 2300 | 0.340 |
Why?
| | Longitudinal Studies | 8 | 2023 | 2480 | 0.330 |
Why?
| | Lipoproteins | 3 | 2016 | 164 | 0.330 |
Why?
| | Pectoralis Muscles | 3 | 2021 | 15 | 0.330 |
Why?
| | Vital Capacity | 6 | 2023 | 257 | 0.320 |
Why?
| | Albuminuria | 4 | 2016 | 197 | 0.320 |
Why?
| | Calcium | 7 | 2018 | 1125 | 0.320 |
Why?
| | Severity of Illness Index | 15 | 2023 | 2633 | 0.310 |
Why?
| | Young Adult | 15 | 2023 | 10674 | 0.300 |
Why?
| | Bronchi | 3 | 2022 | 241 | 0.300 |
Why?
| | Metformin | 2 | 2021 | 293 | 0.300 |
Why?
| | Marijuana Use | 2 | 2021 | 160 | 0.290 |
Why?
| | Case-Control Studies | 14 | 2019 | 3099 | 0.290 |
Why?
| | Genetic Predisposition to Disease | 7 | 2023 | 2227 | 0.280 |
Why?
| | Predictive Value of Tests | 10 | 2019 | 1824 | 0.280 |
Why?
| | Quality of Life | 4 | 2021 | 2374 | 0.280 |
Why?
| | Tandem Mass Spectrometry | 2 | 2019 | 418 | 0.270 |
Why?
| | Hypnotics and Sedatives | 2 | 2019 | 132 | 0.270 |
Why?
| | Proportional Hazards Models | 6 | 2019 | 1105 | 0.270 |
Why?
| | Cross-Sectional Studies | 14 | 2024 | 4510 | 0.270 |
Why?
| | Body Mass Index | 10 | 2022 | 2070 | 0.260 |
Why?
| | Cause of Death | 2 | 2018 | 369 | 0.260 |
Why?
| | Biomarkers | 11 | 2022 | 3549 | 0.260 |
Why?
| | Pulmonary Diffusing Capacity | 3 | 2023 | 58 | 0.250 |
Why?
| | Plaque, Atherosclerotic | 2 | 2023 | 40 | 0.250 |
Why?
| | Antidepressive Agents | 3 | 2019 | 196 | 0.250 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 2 | 2021 | 191 | 0.250 |
Why?
| | Artificial Intelligence | 2 | 2023 | 145 | 0.250 |
Why?
| | Follow-Up Studies | 11 | 2022 | 4507 | 0.240 |
Why?
| | Adrenergic beta-Antagonists | 2 | 2017 | 298 | 0.240 |
Why?
| | Renal Insufficiency | 2 | 2016 | 147 | 0.240 |
Why?
| | United States | 10 | 2023 | 12379 | 0.240 |
Why?
| | Dyspnea | 5 | 2024 | 202 | 0.230 |
Why?
| | Symptom Flare Up | 2 | 2021 | 40 | 0.230 |
Why?
| | Logistic Models | 12 | 2017 | 1877 | 0.220 |
Why?
| | Aged, 80 and over | 9 | 2022 | 6453 | 0.220 |
Why?
| | Multimorbidity | 1 | 2023 | 30 | 0.220 |
Why?
| | Fibrinogen | 3 | 2014 | 148 | 0.220 |
Why?
| | Tomography, Emission-Computed | 1 | 2022 | 58 | 0.220 |
Why?
| | Adiponectin | 4 | 2016 | 220 | 0.220 |
Why?
| | Propofol | 2 | 2021 | 48 | 0.220 |
Why?
| | Limit of Detection | 2 | 2019 | 54 | 0.210 |
Why?
| | Population Health | 1 | 2023 | 45 | 0.210 |
Why?
| | Umbilical Cord | 2 | 2021 | 84 | 0.210 |
Why?
| | Ketosis | 1 | 2022 | 13 | 0.200 |
Why?
| | Cannabidiol | 1 | 2023 | 59 | 0.200 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2023 | 71 | 0.200 |
Why?
| | Cholesterol | 4 | 2011 | 371 | 0.200 |
Why?
| | Cystatin C | 3 | 2011 | 69 | 0.200 |
Why?
| | Hallucinogens | 1 | 2023 | 73 | 0.200 |
Why?
| | Self Report | 3 | 2021 | 696 | 0.200 |
Why?
| | Molecular Epidemiology | 2 | 2019 | 69 | 0.200 |
Why?
| | Protective Agents | 1 | 2021 | 41 | 0.200 |
Why?
| | Hand Strength | 2 | 2022 | 99 | 0.200 |
Why?
| | Sarcopenia | 1 | 2022 | 71 | 0.190 |
Why?
| | Antirheumatic Agents | 1 | 2023 | 255 | 0.190 |
Why?
| | Angiotensin Receptor Antagonists | 1 | 2021 | 82 | 0.190 |
Why?
| | Genome-Wide Association Study | 5 | 2023 | 1314 | 0.190 |
Why?
| | C-Reactive Protein | 2 | 2014 | 368 | 0.180 |
Why?
| | Muscular Atrophy | 1 | 2021 | 80 | 0.180 |
Why?
| | Hepatitis C | 1 | 2023 | 216 | 0.180 |
Why?
| | Delirium | 1 | 2021 | 67 | 0.180 |
Why?
| | 2-Propanol | 1 | 2019 | 21 | 0.180 |
Why?
| | Pulmonary Heart Disease | 1 | 2019 | 6 | 0.180 |
Why?
| | Foam Cells | 1 | 2019 | 14 | 0.170 |
Why?
| | Osteoporosis | 1 | 2022 | 230 | 0.170 |
Why?
| | Hyperostosis | 1 | 2019 | 5 | 0.170 |
Why?
| | Diabetic Nephropathies | 2 | 2016 | 288 | 0.170 |
Why?
| | Calibration | 1 | 2019 | 132 | 0.170 |
Why?
| | Genetic Markers | 2 | 2019 | 338 | 0.170 |
Why?
| | Carbon Monoxide | 1 | 2019 | 63 | 0.170 |
Why?
| | Blood Glucose | 6 | 2022 | 1931 | 0.170 |
Why?
| | Spectrometry, Mass, Electrospray Ionization | 1 | 2019 | 168 | 0.170 |
Why?
| | Regression Analysis | 6 | 2022 | 971 | 0.170 |
Why?
| | Adipose Tissue | 2 | 2017 | 582 | 0.160 |
Why?
| | Anti-Anxiety Agents | 1 | 2019 | 44 | 0.160 |
Why?
| | Surface Properties | 1 | 2019 | 387 | 0.160 |
Why?
| | Diabetes Complications | 2 | 2010 | 212 | 0.160 |
Why?
| | Sexual and Gender Minorities | 1 | 2021 | 138 | 0.160 |
Why?
| | Lung Diseases, Interstitial | 1 | 2023 | 469 | 0.160 |
Why?
| | Drug Overdose | 1 | 2022 | 293 | 0.160 |
Why?
| | Insulin Resistance | 4 | 2017 | 1162 | 0.150 |
Why?
| | Heart Ventricles | 2 | 2020 | 728 | 0.150 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 2019 | 177 | 0.150 |
Why?
| | Population Surveillance | 1 | 2021 | 406 | 0.150 |
Why?
| | Vascular Remodeling | 1 | 2019 | 150 | 0.150 |
Why?
| | Factor Analysis, Statistical | 1 | 2018 | 261 | 0.150 |
Why?
| | HIV Infections | 2 | 2023 | 2446 | 0.150 |
Why?
| | Environmental Monitoring | 1 | 2019 | 281 | 0.150 |
Why?
| | Organ Size | 4 | 2021 | 459 | 0.150 |
Why?
| | Urine | 1 | 2017 | 56 | 0.150 |
Why?
| | Polymorphism, Genetic | 3 | 2011 | 629 | 0.150 |
Why?
| | Linear Models | 6 | 2019 | 802 | 0.150 |
Why?
| | Phenotype | 4 | 2019 | 2891 | 0.150 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2023 | 472 | 0.150 |
Why?
| | Chronic Disease | 1 | 2023 | 1619 | 0.150 |
Why?
| | Obesity | 4 | 2022 | 2661 | 0.140 |
Why?
| | Growth Differentiation Factor 15 | 1 | 2017 | 35 | 0.140 |
Why?
| | Lung Diseases | 1 | 2023 | 693 | 0.140 |
Why?
| | Bronchitis, Chronic | 1 | 2016 | 20 | 0.140 |
Why?
| | Blood Pressure | 5 | 2023 | 1618 | 0.140 |
Why?
| | Machine Learning | 1 | 2019 | 315 | 0.140 |
Why?
| | Prenatal Care | 1 | 2019 | 262 | 0.140 |
Why?
| | Anxiety | 2 | 2022 | 857 | 0.140 |
Why?
| | Plasma | 1 | 2017 | 186 | 0.130 |
Why?
| | Comorbidity | 5 | 2021 | 1487 | 0.130 |
Why?
| | Intraoperative Neurophysiological Monitoring | 1 | 2015 | 15 | 0.130 |
Why?
| | Aortography | 1 | 2015 | 51 | 0.130 |
Why?
| | Respiratory System | 1 | 2016 | 141 | 0.130 |
Why?
| | Arthritis, Rheumatoid | 1 | 2023 | 993 | 0.130 |
Why?
| | Multivariate Analysis | 5 | 2019 | 1458 | 0.130 |
Why?
| | Exercise Tolerance | 3 | 2023 | 227 | 0.130 |
Why?
| | Dexmedetomidine | 1 | 2015 | 46 | 0.130 |
Why?
| | Periodontal Diseases | 1 | 2015 | 58 | 0.130 |
Why?
| | Evoked Potentials | 1 | 2015 | 110 | 0.120 |
Why?
| | Adiposity | 2 | 2022 | 509 | 0.120 |
Why?
| | Polycystic Ovary Syndrome | 1 | 2017 | 157 | 0.120 |
Why?
| | Respiratory Muscles | 1 | 2014 | 32 | 0.120 |
Why?
| | Endothelium, Vascular | 1 | 2021 | 860 | 0.120 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2019 | 2038 | 0.120 |
Why?
| | Evoked Potentials, Somatosensory | 2 | 2015 | 31 | 0.120 |
Why?
| | Health Status | 2 | 2022 | 726 | 0.120 |
Why?
| | Pregnancy Complications | 1 | 2019 | 446 | 0.120 |
Why?
| | Body Composition | 4 | 2021 | 627 | 0.120 |
Why?
| | Subcutaneous Fat | 1 | 2014 | 74 | 0.120 |
Why?
| | Spine | 1 | 2015 | 141 | 0.120 |
Why?
| | Heart | 1 | 2017 | 623 | 0.120 |
Why?
| | Aorta | 1 | 2015 | 358 | 0.110 |
Why?
| | Up-Regulation | 1 | 2016 | 837 | 0.110 |
Why?
| | Sex Distribution | 5 | 2014 | 331 | 0.110 |
Why?
| | Colorado | 6 | 2021 | 4120 | 0.110 |
Why?
| | Orthopedic Procedures | 1 | 2015 | 224 | 0.110 |
Why?
| | Imaging, Three-Dimensional | 1 | 2015 | 497 | 0.100 |
Why?
| | Registries | 1 | 2019 | 1788 | 0.100 |
Why?
| | Triglycerides | 2 | 2011 | 500 | 0.100 |
Why?
| | Blood Vessels | 1 | 2013 | 184 | 0.100 |
Why?
| | Haptoglobins | 1 | 2011 | 49 | 0.100 |
Why?
| | Occupational Exposure | 1 | 2014 | 272 | 0.100 |
Why?
| | Reference Values | 4 | 2023 | 750 | 0.100 |
Why?
| | Adolescent | 6 | 2022 | 18213 | 0.100 |
Why?
| | Hypertension, Pulmonary | 1 | 2022 | 1771 | 0.100 |
Why?
| | Alcohol Drinking | 2 | 2009 | 649 | 0.090 |
Why?
| | Carotid Intima-Media Thickness | 2 | 2023 | 68 | 0.090 |
Why?
| | Retrospective Studies | 8 | 2021 | 12823 | 0.090 |
Why?
| | Walk Test | 2 | 2021 | 51 | 0.090 |
Why?
| | Patient Education as Topic | 2 | 2005 | 687 | 0.090 |
Why?
| | Pediatric Obesity | 1 | 2017 | 513 | 0.090 |
Why?
| | Diagnostic Techniques, Neurological | 1 | 2009 | 8 | 0.090 |
Why?
| | Coma | 1 | 2009 | 30 | 0.090 |
Why?
| | Statistics, Nonparametric | 1 | 2011 | 392 | 0.090 |
Why?
| | Facial Nerve | 1 | 2009 | 31 | 0.090 |
Why?
| | Hypertension | 5 | 2015 | 1179 | 0.090 |
Why?
| | Hypoxia-Ischemia, Brain | 1 | 2009 | 26 | 0.090 |
Why?
| | Monitoring, Intraoperative | 1 | 2009 | 42 | 0.090 |
Why?
| | Aortic Diseases | 1 | 2010 | 94 | 0.080 |
Why?
| | Lymphatic Abnormalities | 1 | 2009 | 18 | 0.080 |
Why?
| | Sensitivity and Specificity | 3 | 2022 | 1740 | 0.080 |
Why?
| | Respiratory Physiological Phenomena | 2 | 2022 | 33 | 0.080 |
Why?
| | Reproducibility of Results | 5 | 2017 | 2818 | 0.080 |
Why?
| | Airway Remodeling | 2 | 2021 | 57 | 0.080 |
Why?
| | Diet, Ketogenic | 1 | 2009 | 34 | 0.080 |
Why?
| | Surveys and Questionnaires | 7 | 2019 | 4661 | 0.080 |
Why?
| | Kidney | 1 | 2016 | 1344 | 0.080 |
Why?
| | Asymptomatic Diseases | 2 | 2021 | 81 | 0.080 |
Why?
| | Anesthesia, Intravenous | 2 | 2021 | 11 | 0.080 |
Why?
| | Odds Ratio | 4 | 2014 | 981 | 0.080 |
Why?
| | Proteinuria | 1 | 2009 | 100 | 0.080 |
Why?
| | Sex Factors | 4 | 2020 | 1758 | 0.080 |
Why?
| | Reproductive History | 1 | 2008 | 12 | 0.080 |
Why?
| | Aorta, Thoracic | 1 | 2010 | 244 | 0.080 |
Why?
| | Angiotensin II Type 2 Receptor Blockers | 1 | 2007 | 8 | 0.080 |
Why?
| | Asthma | 1 | 2021 | 2156 | 0.080 |
Why?
| | Cystatins | 1 | 2007 | 7 | 0.080 |
Why?
| | Coronary Angiography | 2 | 2014 | 309 | 0.080 |
Why?
| | Face | 1 | 2009 | 166 | 0.080 |
Why?
| | Inflammation | 2 | 2021 | 2515 | 0.070 |
Why?
| | Radiography | 3 | 2016 | 843 | 0.070 |
Why?
| | Prognosis | 4 | 2021 | 3390 | 0.070 |
Why?
| | Time Factors | 6 | 2015 | 6240 | 0.070 |
Why?
| | Uric Acid | 1 | 2010 | 349 | 0.070 |
Why?
| | Life Style | 1 | 2009 | 432 | 0.070 |
Why?
| | Heart Rate | 1 | 2010 | 708 | 0.070 |
Why?
| | Dietary Fats | 1 | 2009 | 305 | 0.070 |
Why?
| | Mortality | 2 | 2019 | 291 | 0.070 |
Why?
| | Incidence | 3 | 2019 | 2377 | 0.070 |
Why?
| | Contraception | 1 | 2008 | 117 | 0.070 |
Why?
| | Renin-Angiotensin System | 1 | 2007 | 82 | 0.070 |
Why?
| | Apolipoproteins A | 1 | 2006 | 18 | 0.070 |
Why?
| | Apolipoproteins C | 1 | 2006 | 6 | 0.070 |
Why?
| | Propensity Score | 2 | 2019 | 237 | 0.070 |
Why?
| | Kidney Diseases | 1 | 2010 | 436 | 0.070 |
Why?
| | Receptors, Interleukin-2 | 1 | 2005 | 65 | 0.070 |
Why?
| | Cluster Analysis | 2 | 2019 | 478 | 0.070 |
Why?
| | Internationality | 2 | 2017 | 149 | 0.060 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2010 | 381 | 0.060 |
Why?
| | Receptors, IgG | 1 | 2005 | 66 | 0.060 |
Why?
| | Chi-Square Distribution | 3 | 2010 | 513 | 0.060 |
Why?
| | Antihypertensive Agents | 2 | 2007 | 434 | 0.060 |
Why?
| | Pregnancy | 3 | 2023 | 5653 | 0.060 |
Why?
| | Abdominal Wall | 1 | 2004 | 26 | 0.060 |
Why?
| | Apolipoprotein C-III | 2 | 2019 | 13 | 0.060 |
Why?
| | Haplotypes | 1 | 2006 | 472 | 0.060 |
Why?
| | Glomerular Filtration Rate | 3 | 2016 | 686 | 0.060 |
Why?
| | Cholesterol, LDL | 1 | 2005 | 317 | 0.060 |
Why?
| | Glucose Clamp Technique | 2 | 2017 | 191 | 0.060 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2005 | 350 | 0.060 |
Why?
| | Insulin | 3 | 2022 | 2135 | 0.050 |
Why?
| | Antigens, CD | 1 | 2005 | 450 | 0.050 |
Why?
| | Nutrition Surveys | 1 | 2024 | 228 | 0.050 |
Why?
| | Blood Platelets | 1 | 2005 | 328 | 0.050 |
Why?
| | Herpesvirus 4, Human | 1 | 2023 | 123 | 0.050 |
Why?
| | Genotype | 3 | 2018 | 1854 | 0.050 |
Why?
| | Multifactorial Inheritance | 1 | 2023 | 141 | 0.050 |
Why?
| | Morbidity | 1 | 2022 | 283 | 0.050 |
Why?
| | Radiography, Thoracic | 2 | 2014 | 161 | 0.050 |
Why?
| | Muscles | 1 | 2022 | 328 | 0.050 |
Why?
| | Child, Preschool | 3 | 2023 | 9322 | 0.050 |
Why?
| | Lung Volume Measurements | 1 | 2021 | 46 | 0.050 |
Why?
| | Biological Variation, Population | 1 | 2021 | 21 | 0.050 |
Why?
| | Reaction Time | 2 | 2015 | 375 | 0.050 |
Why?
| | Survival Analysis | 2 | 2017 | 1240 | 0.050 |
Why?
| | Hepacivirus | 1 | 2023 | 227 | 0.050 |
Why?
| | Protective Factors | 1 | 2021 | 88 | 0.050 |
Why?
| | Adrenergic beta-2 Receptor Agonists | 1 | 2021 | 32 | 0.050 |
Why?
| | Plethysmography | 1 | 2021 | 122 | 0.050 |
Why?
| | Substance Abuse Detection | 1 | 2021 | 61 | 0.050 |
Why?
| | Anesthesia, General | 1 | 2021 | 48 | 0.050 |
Why?
| | Hospitals, Urban | 1 | 2021 | 129 | 0.050 |
Why?
| | Diabetes Mellitus | 1 | 2009 | 930 | 0.050 |
Why?
| | Bayes Theorem | 1 | 2022 | 341 | 0.050 |
Why?
| | Cigarette Smoking | 1 | 2021 | 80 | 0.050 |
Why?
| | Treatment Outcome | 3 | 2021 | 9256 | 0.040 |
Why?
| | Hospitals, Pediatric | 2 | 2017 | 489 | 0.040 |
Why?
| | Homosexuality, Male | 1 | 2021 | 166 | 0.040 |
Why?
| | Oligodeoxyribonucleotides, Antisense | 1 | 2019 | 8 | 0.040 |
Why?
| | Lipids | 2 | 2017 | 584 | 0.040 |
Why?
| | rab4 GTP-Binding Proteins | 1 | 2019 | 8 | 0.040 |
Why?
| | Cytochrome P-450 CYP2B6 | 1 | 2019 | 9 | 0.040 |
Why?
| | Cytochrome P450 Family 2 | 1 | 2019 | 12 | 0.040 |
Why?
| | Proof of Concept Study | 1 | 2019 | 45 | 0.040 |
Why?
| | RNA, Viral | 1 | 2023 | 565 | 0.040 |
Why?
| | Multidetector Computed Tomography | 1 | 2019 | 26 | 0.040 |
Why?
| | Analysis of Variance | 2 | 2014 | 1239 | 0.040 |
Why?
| | Exercise | 1 | 2009 | 1627 | 0.040 |
Why?
| | Birth Weight | 1 | 2022 | 466 | 0.040 |
Why?
| | Administration, Inhalation | 1 | 2021 | 642 | 0.040 |
Why?
| | Aryl Hydrocarbon Hydroxylases | 1 | 2019 | 42 | 0.040 |
Why?
| | Bronchodilator Agents | 1 | 2021 | 249 | 0.040 |
Why?
| | Bone Density | 1 | 2022 | 444 | 0.040 |
Why?
| | Genomics | 1 | 2023 | 658 | 0.040 |
Why?
| | Electroencephalography | 1 | 2021 | 367 | 0.040 |
Why?
| | Europe | 1 | 2019 | 349 | 0.040 |
Why?
| | Systems Biology | 1 | 2018 | 57 | 0.040 |
Why?
| | Drug Therapy, Combination | 1 | 2021 | 965 | 0.040 |
Why?
| | Atmospheric Pressure | 1 | 2017 | 19 | 0.040 |
Why?
| | Electrocardiography | 2 | 2010 | 548 | 0.040 |
Why?
| | Maternal Health Services | 1 | 2019 | 82 | 0.040 |
Why?
| | Electric Impedance | 1 | 2017 | 99 | 0.040 |
Why?
| | Adrenal Cortex Hormones | 1 | 2021 | 508 | 0.040 |
Why?
| | Diagnostic Imaging | 1 | 2019 | 294 | 0.040 |
Why?
| | Total Lung Capacity | 1 | 2016 | 32 | 0.040 |
Why?
| | Glucose | 1 | 2022 | 931 | 0.040 |
Why?
| | Michigan | 1 | 2017 | 95 | 0.040 |
Why?
| | Bronchial Arteries | 1 | 2016 | 11 | 0.040 |
Why?
| | RNA | 1 | 2023 | 827 | 0.040 |
Why?
| | Causality | 1 | 2017 | 110 | 0.040 |
Why?
| | Kaplan-Meier Estimate | 1 | 2018 | 825 | 0.030 |
Why?
| | Urban Population | 1 | 2019 | 404 | 0.030 |
Why?
| | Area Under Curve | 1 | 2016 | 285 | 0.030 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2017 | 475 | 0.030 |
Why?
| | Cognition | 1 | 2023 | 988 | 0.030 |
Why?
| | Cough | 1 | 2016 | 101 | 0.030 |
Why?
| | Evoked Potentials, Visual | 1 | 2015 | 31 | 0.030 |
Why?
| | Evoked Potentials, Motor | 1 | 2015 | 35 | 0.030 |
Why?
| | Statistics as Topic | 1 | 2016 | 299 | 0.030 |
Why?
| | Anesthetics, Intravenous | 1 | 2015 | 33 | 0.030 |
Why?
| | Muscle Strength | 1 | 2018 | 278 | 0.030 |
Why?
| | Automation | 1 | 2015 | 74 | 0.030 |
Why?
| | Sex Characteristics | 2 | 2014 | 648 | 0.030 |
Why?
| | Physical Endurance | 1 | 2016 | 225 | 0.030 |
Why?
| | ROC Curve | 1 | 2016 | 460 | 0.030 |
Why?
| | Stroke | 1 | 2003 | 1021 | 0.030 |
Why?
| | Gastroesophageal Reflux | 1 | 2017 | 239 | 0.030 |
Why?
| | Piperidines | 1 | 2015 | 168 | 0.030 |
Why?
| | Mice | 2 | 2021 | 15308 | 0.030 |
Why?
| | Pandemics | 1 | 2022 | 1354 | 0.030 |
Why?
| | Inflammation Mediators | 1 | 2017 | 486 | 0.030 |
Why?
| | Dyslipidemias | 1 | 2015 | 159 | 0.030 |
Why?
| | Hypercholesterolemia | 1 | 2014 | 91 | 0.030 |
Why?
| | Quality Improvement | 1 | 2021 | 956 | 0.030 |
Why?
| | Mice, Knockout | 1 | 2019 | 2648 | 0.030 |
Why?
| | Angiography | 1 | 2013 | 179 | 0.030 |
Why?
| | Vascular Stiffness | 1 | 2017 | 416 | 0.030 |
Why?
| | Mice, Inbred C57BL | 1 | 2021 | 4839 | 0.030 |
Why?
| | Exercise Test | 1 | 2014 | 541 | 0.020 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2011 | 322 | 0.020 |
Why?
| | Double-Blind Method | 1 | 2015 | 1670 | 0.020 |
Why?
| | Gene Frequency | 1 | 2011 | 507 | 0.020 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2016 | 572 | 0.020 |
Why?
| | Median Nerve | 1 | 2009 | 21 | 0.020 |
Why?
| | Radiographic Image Interpretation, Computer-Assisted | 1 | 2010 | 108 | 0.020 |
Why?
| | Facial Paralysis | 1 | 2009 | 16 | 0.020 |
Why?
| | Intra-Abdominal Fat | 1 | 2010 | 89 | 0.020 |
Why?
| | Artifacts | 1 | 2009 | 124 | 0.020 |
Why?
| | Observer Variation | 1 | 2009 | 307 | 0.020 |
Why?
| | Animals | 2 | 2021 | 32736 | 0.020 |
Why?
| | Personality Inventory | 1 | 2009 | 133 | 0.020 |
Why?
| | Chromatography, Liquid | 1 | 2010 | 350 | 0.020 |
Why?
| | Age Factors | 2 | 2007 | 2950 | 0.020 |
Why?
| | Algorithms | 1 | 2015 | 1505 | 0.020 |
Why?
| | Diabetic Neuropathies | 1 | 2009 | 79 | 0.020 |
Why?
| | Health Surveys | 1 | 2009 | 443 | 0.020 |
Why?
| | Electromyography | 1 | 2009 | 324 | 0.020 |
Why?
| | Age of Onset | 1 | 2009 | 456 | 0.020 |
Why?
| | Angiotensins | 1 | 2007 | 11 | 0.020 |
Why?
| | Receptor, Angiotensin, Type 1 | 1 | 2007 | 22 | 0.020 |
Why?
| | Contraceptive Agents, Female | 1 | 2008 | 65 | 0.020 |
Why?
| | Preoperative Care | 1 | 2009 | 324 | 0.020 |
Why?
| | Peptidyl-Dipeptidase A | 1 | 2007 | 55 | 0.020 |
Why?
| | Diabetic Retinopathy | 1 | 2009 | 153 | 0.020 |
Why?
| | Patient Selection | 1 | 2010 | 656 | 0.020 |
Why?
| | Self Care | 1 | 2009 | 355 | 0.020 |
Why?
| | Amino Acid Substitution | 1 | 2006 | 273 | 0.020 |
Why?
| | Hospitalization | 1 | 2014 | 1762 | 0.020 |
Why?
| | Waist-Hip Ratio | 1 | 2004 | 31 | 0.020 |
Why?
| | Platelet Aggregation | 1 | 2005 | 89 | 0.020 |
Why?
| | Radiography, Abdominal | 1 | 2004 | 32 | 0.020 |
Why?
| | Age Distribution | 1 | 2005 | 340 | 0.010 |
Why?
| | Anthropometry | 1 | 2004 | 188 | 0.010 |
Why?
| | Feeding Behavior | 1 | 2009 | 590 | 0.010 |
Why?
| | Alleles | 1 | 2006 | 816 | 0.010 |
Why?
| | Neoplasms | 1 | 2016 | 2146 | 0.010 |
Why?
| | Flow Cytometry | 1 | 2005 | 1063 | 0.010 |
Why?
| | Promoter Regions, Genetic | 1 | 2006 | 1141 | 0.010 |
Why?
| | Risk | 1 | 2003 | 842 | 0.010 |
Why?
| | Hyperglycemia | 1 | 2003 | 308 | 0.010 |
Why?
| | Oxidative Stress | 1 | 2006 | 1148 | 0.010 |
Why?
| | DNA | 1 | 2006 | 1372 | 0.010 |
Why?
| | Postoperative Complications | 1 | 2009 | 2198 | 0.010 |
Why?
| | Child | 1 | 2017 | 18876 | 0.010 |
Why?
| | Hypoglycemic Agents | 1 | 2005 | 1035 | 0.010 |
Why?
| | Infant | 1 | 2009 | 8121 | 0.010 |
Why?
|
|
Kinney's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|